The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 study of CRLX301, a novel nanoparticle-drug conjugate (NDC) containing docetaxel (DOC), in patients with refractory solid tumors.
 
Ben Markman
Travel, Accommodations, Expenses - Cerulean Pharma
 
Paul L. De Souza
Honoraria - Janssen
Consulting or Advisory Role - Astellas Pharma; GlaxoSmithKline; Janssen; Pfizer
Research Funding - Multiple pharma companies
Expert Testimony - Janssen
 
Elizabeth Claire Dees
Consulting or Advisory Role - Amgen (I); Novartis (I)
Research Funding - Bayer; Genentech/Roche; Lilly/ImClone; Merck; Millennium; Novartis; Pfizer
 
Tara C. Gangadhar
Honoraria - Merck Sharp & Dohme
 
Adam Cooper
Honoraria - Bristol-Myers Squibb
 
Aflah Roohullah
No Relationships to Disclose
 
Vishal Boolell
No Relationships to Disclose
 
William Zamboni
Honoraria - Cerulean Pharma; ChemoGLO; Crystal Pharma; Merrimack
Consulting or Advisory Role - Cerulean Pharma; ChemoGLO; Crystal Pharma; Mallinckrodt; Merrimack
Research Funding - Mallinckrodt; Merrimack
Patents, Royalties, Other Intellectual Property - ChemoGLO
 
Curran Murphy
Employment - Cerulean Pharma; Takeda (I)
Stock and Other Ownership Interests - Cerulean Pharma
 
Adrian Mario Senderowicz
Leadership - Puma Biotechnology
Stock and Other Ownership Interests - Cerulean Pharma
Honoraria - Cerulean Pharma
Consulting or Advisory Role - Cerulean Pharma
Travel, Accommodations, Expenses - Cerulean Pharma; Sanofi
 
HongWei Wang
Employment - Cerulean Pharma
Stock and Other Ownership Interests - Cerulean Pharma